-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
June 2018
-
Motivated, Engaged, and Organized: The New Molecular Cohorts of Lung Cancer
By D.R. Camidge Posted: June 2018 Just as physicians and scientists no longer treat lung cancer as a single disease because of molecular distinctions, patient advocacy groups also are becoming organized along molecular lines. In 2015, Janet Freeman-Daily, Lisa Goldman, and Tori Tomalia—all ROS1– positive NSCLC survivors—co-founded a private Facebook group, ”ROS1 Positive (ROS1+) Cancer.”…
-
HLA LOH As an Immune Evasive Mechanism in TRACERx NSCLC
By Rachel Rosenthal, PhD, MSc, andCharles Swanton, FRCP, BSc, PhD Posted: June 2018 An evolving tumor and the immune system continuously adapt to each other. As a tumor develops increasing numbers of somatic alterations and disregulated genes, it must also find ways to avoid immune detection and elimination by activated immune cells.1 One route to…
-
Israel's Parliament Hosts IASLC CEO Dr. Fred R. Hirsch
By Shani Shilo, DMD, PhD, andNir Peled, MD, PhD, FCCP Posted: June 2018 On March 6, 2018, the Israeli parliament, the Knesset, held a Science and Technology Committee meeting devoted to lung cancer, new technologies, and their effects on the future of care. The meeting was an initiative of the Israel Lung Cancer Foundation and…
-
NCCN Guidelines Updated for 2018: Keeping Pace with Data
By Gregory J. Riely, MD Posted: June 2018 The changes seen in the 2018 update of the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of patients with NSCLC reflect the rapid and significant progress we have observed in the treatment of lung cancer over the past 12…
-
Fabrice Barlesi, MD
Posted: June 2018 The 2018 Heine H. Hansen Award recipient was IASLC Lung Cancer News Associate Editor Fabrice Barlesi, MD. The award was presented at the 2018 European Lung Cancer Congress (ELCC), sponsored by the European Society for Medical Oncology (ESMO) and the IASLC. Dr. Barlesi is professor of medicine at the University of Aix…
-
Frances Shepherd, MD
Posted: June 2018 IASLC past-president Frances Shepherd, MD, has been awarded the 2018 Canada Gairdner Wightman Award for outstanding career leadership in medicine and medical science. Dr. Shepherd is a professor in the Department of Medicine, Scott Taylor Chair in Lung Cancer Research, and senior staff physician at the Princess Margaret Cancer Centre. She has…
-
Pasi A. Janne, MD, PhD
Posted: June 2018 Pasi A. Janne, MD, PhD, was awarded the Second AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research. The award is given to a cancer researcher who has conducted highly meritorious laboratory, translational, or clinical cancer research anywhere in the world at a relatively early state in his…
-
Primo N. Lara, Jr., MD
Posted: June 2018 Primo N. Lara, Jr., MD, has been named director of the National Cancer Institute–designated UC Davis Comprehensive Cancer Center, leading a team of more than 300 scientists serving more than 10,000 new adult and pediatric patients yearly. As director, Dr. Lara will hold the Codman-Radke Chair in Cancer Research and will serve…
-
The Long Road Home
Figure. Prevalance of Water Pipe Usage Is Virtually at Epidemic Proportion in Parts of the Middle East Sources: Vardavas C, Filippidis F, Agaku I. http://tobaccocontrol.bmj.com. Accessed April 11, 2018. McKelvey KL, Wilcox ML, Madhivanan P, et al. Eur J Public Health. 2013;23(5):862-867. Florida Department of Health; 2012 Florida Youth Tobacco Survey. tobaccoatlas.org. Accessed April 11,…
-
EGFR-Targeted Therapy: A New Beginning
Highlights from the IASLC 18th Lung Cancer Targeted Therapies Meeting keynote address. By Suresh S. Ramalingam, MD Posted: June 2018 EGFR-targeted therapy has entered a new phase as the result of several important advances in recent years. It is now well established that EGFR tyrosine kinase inhibitors (TKIs) are the preferred standard of care for…
View ILCN Archives
Provider Resources
Popular Articles